Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT500 in MASLD Complicated With Chronic Hepatitis B
NCT07589400Phase 1Not yet recruiting
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of azithromycin in metabolic dysfunction-associated steatotic liver disease (MASLD) and Chronic Hepatitis B (CHB) (6 arms), sponsored by Xiamen Tebao Biological Engineering Co., Ltd. Primary endpoints: Adverse Event and Serious Adverse Event. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
azithromycin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07589400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589400.